AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02141178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Study NCT00875719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen concentrators versus constant flow axygen
Description: Each patient performed 2 walking tests, and received oxygen supplementation from a portable concentrator or a liquid oxygen source, in a random order.
Study NCT00875719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen concentrator
Description: comparison walk distance and saturation with continuous oxygen compared to intermittent oxygen
Study NCT03896490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control Training
Description: Infants watch interactive cartoons that respond to infants' direction of gaze. An eye-tracker records the infant's eye movements in real time, relaying this information to the computer. These presentations trigger motivating stimuli (cartoon animations with child-friendly sounds) every time the infant fulfills the demands of a task (e.g. when the infant looks at a character on the screen avoiding to be distracted by other objects moving across the screen). The length of training sessions varies depending on infants' engagement with stimuli and time criteria.
Study NCT03896490 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control procedure involves presentation of cartoons on a screen, while infants' gaze direction is recorded using the same eye-tracker and camera. The crucial difference is that the cartoons in this case are not interactive, thus do not change depending on infants' gaze direction. To ensure presentations in the control procedure are similar in length to those of the intervention group, infants in the control group are matched infant-by-infant and visit-by-visit with participants in the ACT treatment group: Infants in the control group see a replay of the session of the matched treated infant. Therefore, while the presentation is exactly the same (i.e. same length and same stimuli) for the treated and the control child, in the latter case the presentation is not interactive (i.e. not generated contingently on the infants' visual behaviour).
Study NCT02233790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.
Study NCT02233790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
Study NCT02978235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS4464
Description: Intravenous (IV) Infusion
Study NCT02599987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POWERbreathe® Classic Light
Description: Inspiratory Muscle Training
Study NCT02599987 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: POWERbreathe® Classic Light
Description: Inspiratory Muscle Training
Study NCT00685347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI
Description: 1. levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).~2. Arm #A~3. Xopenex HFA MDI
Study NCT00685347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Albuterol
Description: 1. racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).~2. Arm #B~3. Proventil HFA MDI
Study NCT03553784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group delivered Low Intensity Cognitive Behavioural Therapy
Description: The intervention is group-delivered, low-intensity CBT similar to that used in IAPT (Improving Access to Psychological Therapies) Services in England. This intervention is already being offered as part of standard care at the Intervention site, and will not be altered by the study protocol, other than the requirement to complete a few more questionnaires. The intervention group meets weekly for eight weeks, and is facilitated by a clinical psychologist, a psychological well-being practitioner and a clinical nurse specialist from the medical oncology team. Content of the intervention is broad CBT, combining aspects of second-wave CBT, with elements of Narrative Therapy and ACT.
Study NCT03518697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise program
Description: The exercise program is planned as a low-threshold exercise program with low barriers to participate. Patients will be asked about their interests and preferences of sports activities to conceive the exercise program together with the patients.
Study NCT02383121 — intervention group
Intervention type: DRUG
Intervention: Midodrine
Description: Not appliciable
Study NCT02033499 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SMBG
Description: Blood glucose levels are tested once daily.
Study NCT01881100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resin infiltration
Description: The test group (41 children) had caries lesions treated with the resin infiltration technique using Icon by the following procedure: rubber dam applying; etching with 15% hydrochloric acid for 120 s; surface rinsing and drying; dehydrating with ethanol for 30 s and air-drying; infiltrant resin infiltration with a syringe for 180 s; resin polymerization (polymerized by blue light - wavelength of 450 nm and intensity of 800mW/cm2; resin reapplication for 60 s and polymerization; rubber dam removal, and working on the infiltrated lesion with polishing rubbers. After the procedure fluoride varnish was applied.
Study NCT04049552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin 8% Ointment
Description: A compounded ointment containing 8% rapamycin
Study NCT04049552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Petrolatum ointment placebo
Study NCT05737329 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Transdermal estradiol gel 0.1% 1.5mg/ day
Description: Estradiol gel 0.1% 1.5mg/ daily + Micronized Progesterone 200mg
Study NCT05737329 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Transdermal estradiol gel 0.1% 2.0mg/ day
Description: Estradiol gel 0.1% 2.0mg/ daily + Micronized Progesterone 200mg
Study NCT00036777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00036777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV
Study NCT00036777 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01859390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AquADEKs-2
Description: AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
Study NCT01859390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: control multivitamin
Description: The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
Study NCT01859390 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: control multivitamin
Description: The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
Study NCT01448031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsule ASA 81mg/esomeprazole 20mg
Description: Multiple doses administered on Day 1 to 5
Study NCT01448031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylzuur Apotex Cardio
Description: Multiple doses administered on Day 1 to 5
Study NCT04189276 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ETV/TDF+T101 No.1
Description: Patients will be injected with T101 once on Day1 (Week0), Day8 (Week1), Day15 (Week2), Day106 (Week15), Day113 (Week16), Day120 (Week17), Day211 (Week30), Day218 (Week31), Day225 (Week32), Day316 (Week45), Day323 (Week46), Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
Study NCT04189276 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ETV/TDF+T101 No.2
Description: Patients will be injected with T101 once on Day1 (Week0), Day106 (Week15), Day211 (Week30), Day316 (Week45); ETV or TDF will be administrated once each day successively until Day420.
Study NCT04189276 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ETV or TDF
Description: Patients will be administrated ETV or TDF once each day successively until Day420.
Study NCT04189276 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ETV/TDF+Peg-IFNα-2b
Description: Patients will be administrated Peg-IFNα-2b successively once a week until Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.
Study NCT04621942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inertial rehabilitation
Description: Inertial rehabilitation was performed twice a week (Monday and Thursday, between 5:00 and 8:00 PM) for 6 weeks using Cyklotren device (Inerion, Poland). Exercises were conducted by the same 2 researchers. Each training session included warm-up and 4 sets of shoulder ﬂexors, extensors, abductors, and adductors, with the right and left arms worked separately (16 sets for left and 16 sets for right arm). Each set lasted 15 seconds, a 2-minute break occurred between consecutive sets (without rest period between right and left arm). For all trained muscles 5 kg load was applied. During the training participants developed 70% of their maximal force achieved during the strength measurement. Participants observed developed during training force value displayed on-line on the screen. Cyklotren software allows to set the upper and lower limit of force; when developed strength was to low or to high a beep signal was emitted to correct participant force.
Study NCT04621942 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gymnastic rehabilitation
Description: All women (from T and C group) participated in rehabilitation gymnastics twice a week during experiment (6 weeks). The gymnastics was conducted by a physiotherapist specializing in rehabilitation of women after mastectomy. The trehabilitation session lasted 45 minutes. During the sessions, the women mainly performed exercises involved shoulders, chest and the upper limbs muscles. Moreover, abdomen and back muscles were exercised.
Study NCT04621942 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gymnastic rehabilitation
Description: All women (from T and C group) participated in rehabilitation gymnastics twice a week during experiment (6 weeks). The gymnastics was conducted by a physiotherapist specializing in rehabilitation of women after mastectomy. The trehabilitation session lasted 45 minutes. During the sessions, the women mainly performed exercises involved shoulders, chest and the upper limbs muscles. Moreover, abdomen and back muscles were exercised.
Study NCT01881100 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish
Description: All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
Study NCT01881100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluoride varnish
Description: All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
Study NCT01249339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 1g, single dose. One pouch administered over 30 minutes.
Study NCT01821469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychoeducation
Description: Bipolar disorders are educated to learn about their pathology
Study NCT01740674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic data collection
Study NCT01750138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Study NCT01750138 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose powder
Study NCT03827954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HeartMapp+CT
Description: HeartMapp+CT is a mobile system that includes physiological modules that support self-monitoring and exercises that promote heart health, and computerized plasticity-based adaptive cognitive training modules that train participants to enhance cognitive functions and ultimately heart failure outcomes.
Study NCT04396834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin Oral Tablet
Description: Lorcasering 10mg Oral Tablet (BID)
Study NCT04396834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo Oral Tablet (BID)
Study NCT04390737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HH2853 Tablets
Description: Proposed daily dose (BID): 50mg, 100mg, 200mg, 400mg, 600mg, 800mg, 1000mg. It is possible for additional and/or intermediate dose levels to be added during the course of the study. Cohorts may be added at any dose level below the MTD in order to better understand safety, PK or PD.
Study NCT03747926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564
Description: single-rising oral dose
Study NCT03747926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single-rising oral dose
Study NCT05308251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein Mesh Hernioplasty
Description: The inguinal canal was opened and the hernia sac was dissected from the spermatic cord The deep inguinal ring was tightened with one or two polypropylene 2/0 sutures. The posterior wall of the inguinal canal was supported using the standard polypropylene mesh and fixed with 2/0 polyproline. The ilioinguinal nerve, iliohypogastric nerve, and genital branch of the genitofemoral nerve were preserved and care was taken to prevent entrapment.
Study NCT05308251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein Mesh Hernioplasty
Description: The inguinal canal was opened and the hernia sac was dissected from the spermatic cord The deep inguinal ring was tightened with one or two polypropylene 2/0 sutures. The posterior wall of the inguinal canal was supported using the standard polypropylene mesh and fixed with 2/0 polyproline. The ilioinguinal nerve, iliohypogastric nerve, and genital branch of the genitofemoral nerve were preserved and care was taken to prevent entrapment.
Study NCT01249339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
Study NCT01249339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal Administration of nicotine
Description: Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
Study NCT03367026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine Oral Product
Description: Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or Jejunum tube) of ivabradine for 4 days.~Day 1 :~2.5 mg ivabradine b.i.d. if heart rate ≥90 bpm~Day 2,3,4:~2.5 mg ivabradine b.i.d. if 60bpm≥heart rate\<90bpm. 5.0mg ivabradine b.i.d. if heart rate ≥90bpm
Study NCT01237093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1. Meat, no fish or soda
Description: weight maintaining diet with meat but no fish or soda
Study NCT01237093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2. Meat and soda, no fish
Description: weight maintaining diet with meat and soda but no fish
Study NCT01237093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3. Meat and fish, no soda
Description: weight maintaining diet with meat and fish but no soda
Study NCT01237093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4. Meat and fish and soda
Description: weight maintaining diet with meat, fish and soda
Study NCT01237093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5. Fish, no meat or soda
Description: weight maintaining diet with fish but no meat or soda
Study NCT01237093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6. Fish and soda, no meat
Description: weight maintaining diet with fish and soda but no meat
Study NCT01237093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7. No meat, fish or soda
Description: weight maintaining diet with no meat, no fish, and no soda (vegetarian)
Study NCT01237093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 8. Soda, no meat or fish
Description: weight maintaining diet with soda but no meat or fish (vegetarian + soda)
Study NCT03716713 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CeraShield Endotracheal Tube
Description: Subjects requiring mechanical ventilation with be intubated with the CeraShield ETT
Study NCT01349569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
Study NCT01349569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Myeloma Vaccine
Description: A total of 4 vaccines will be administered. The first three at monthly intervals and a booster at 6 months from the initial vaccine. Each vaccination will consist of five total intra-dermal injections, two each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). Each dose will be administered on an outpatient basis. The subject must be observed in the clinic for at least 30 minutes after vaccination is completed.
Study NCT01349569 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar-13
Description: Prevnar-13 will be administered at 0.5ml dose by intramuscular injection at the same time as GVAX vaccine.
Study NCT04898101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.
Study NCT04898101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microtracer [14C]ACP-196
Description: Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.
Study NCT04592523 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT00945425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: oral capsule, once or twice daily, 7 days
Study NCT02048943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dovitinib lactate
Description: Given PO
Study NCT02048943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT02048943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT02048943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02048943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00945425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral capsule, once or twice daily, 7 days
Study NCT00549198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine and efavirenz
Study NCT00549198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine and efavirenz
Study NCT02938494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-123 Lotion
Description: Lotion
Study NCT04165317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06801591
Description: A monoclonal antibody (mAb) that blocks the interaction between PD-1 and PD-L1/PD-L2.
Study NCT04165317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guerin
Description: Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
Study NCT04165317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin
Description: Immunotherapy treatment approved by FDA for patients with high-risk non-muscle invasive bladder cancer
Study NCT00626522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide and formoterol
Description: once daily
Study NCT00626522 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aclidinium bromide and formoterol placebo
Description: once daily
Study NCT03618238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12 mg daily for continus 14 days every 21 days